Post Profile






Big Pharma vs Big Pharma in court battles over biosimilar drugs

ZURICH (Reuters) - The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals' complex biological medicines.
read more

share

Related Posts


What journalists and consumers should know about the tug-of-war between biologics and generic ‘biosimilars’

Health : Health News Watchdog blog

When the body attacks itself–known as an autoimmune disease–one of the most powerful drug options patients have is what’s known commonly as a “biologic drug.” In the last few decades, these drugs, known medically as biologic respons...

What do patients know about generic biotech drugs?

Health : Reuters: Health

(Reuters Health) - Many patients haven’t heard of “biosimilars,” generic versions of complex biotech drugs, and even some who say they’re familiar with these medicines may still be confused about them, a small European survey sugges...

New biologic drug for rheumatoid arthritis approved by the FDA

Health : Bel Marra Health

The FDA has recently approved a new biologic drug to treat rheumatoid arthritis and other inflammatory diseases. Known as Erelzi, the drug is a biosimilar for Enbrel, which was previously approved by the FDA. A biosimilar is a biolo...

Biosimilars And Biobetters Conference - Next Generation Monoclonal Antibody Development And Clinical Challenges With Biosimilar Drug Development

Health : Medical News Today

Also known as follow-on biologics, biosimilars are not like generic pharmaceuticals which can be analyzed in a laboratory to confirm that they are exact copies of chemical drugs...

Novartis bid to sell new biosimilar crimped by U.S. court battles

Health : Reuters: Health

ZURICH (Reuters) - Novartis has won U.S. approval for a copy of Amgen's blockbuster arthritis drug Enbrel, but the Swiss drugmaker's bid to muscle in on the medicine's $4.7 billion in annual U.S. revenue remains blocked by court bat...

Comments


Copyright © 2016 Regator, LLC